NCT03418961: S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

NCT03418961
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients on lapatinib without trastuzumab or patients planning to have HER-2 targeted therapy & anthracyclines at the same time
https://clinicaltrials.gov/show/NCT03418961

Comments are closed.

Up ↑